Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.33 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6757301 | 0.83 | KCNK3 (0.37) | KCNK3ALDH1A1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL6757299 | 0.83 | KCNK3 (0.37) | KCNK3ALDH1A1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL6761469 | 0.75 | KCNN2 (0.40) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL6761467 | 0.75 | KCNN2 (0.40) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL6762493 | 0.75 | SMN1; SMN2 (0.40) | KCNK3ALDH1A1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL6759762 | 0.68 | KDM4E (0.38) | KCNK3ALDH1A1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL6762067 | 0.68 | SMN1; SMN2 (0.36) | KCNK3ALDH1A1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL6759736 | 0.67 | KDM4E (0.38) | KCNK3ALDH1A1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL6759646 | 0.65 | KCNK3 (0.38) | KCNK3ALDH1A1KDM4EKMT2A | |
| SCHEMBL6879252 | 0.65 | KMT2A (0.37) | KCNK3ALDH1A1KDM4EKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106635-A1 | having small-conductance potassium channel (SK) blocking activity | TANABE SEIYAKU CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106635-A1 | having small-conductance potassium channel (SK) blocking activity | KCNN1, KCNN2, KCNN3 | ACHE 1863/4885KCNK3 30/4885ALDH1A1 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.